Slaughter and May is advising Alliance Pharma plc ("Alliance”) on the recommended acquisition by Aegros Bidco Limited ("Bidco") for the entire issued and to be issued ordinary share capital of Alliance, to be effected by means of a court-sanctioned scheme of arrangement. The cash offer values Alliance at approximately £349.7 million and represents a premium of approximately 40.9% to Alliance’s closing price prior to the start of the offer period, and a 64.6% premium on a 12 month VWAP basis. As an alternative to the cash offer, shareholders may elect to exchange some or all of their shares for rollover shares to be issued by an indirect holding company of Bidco. Subject to satisfaction of certain conditions, the transaction is expected to complete in the first half of 2025.
Alliance is an international consumer healthcare company targeting the markets of France, USA, Germany, China and the UK with a bespoke operating model within each market to increase the reach of their brand. Headquartered in the UK, Alliance operates from eight offices around the world and has an extensive network of distributors to serve customers in more than 100 countries.